Immunotherapy of MDS: you can run, but you can't hide.
Immunotherapy of MDS: you can run, but you can't hide.
Clin Cancer Res. 2017 Dec 28;:
Authors: Fuchs EJ
Abstract
The hypomethylating agent decitabine induces expression of the cancer testis antigen NY-ESO-1 in the myeloid cells of patients with myelodysplastic syndrome (MDS). MDS patients treated with decitabine and an NY-ESO-1 vaccine developed NY-ESO-1-specific T cell responses directed against their abnormal myeloid cells, raising hopes for combinatorial immunotherapy of this disease.
PMID: 29284705 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Fuchs EJ Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Immunotherapy | Myelodysplastic Syndrome | Vaccines